OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer
Harshabad Singh, Rachel B. Keller, Kevin S. Kapner, et al.
Clinical Cancer Research (2023) Vol. 29, Iss. 22, pp. 4627-4643
Open Access | Times Cited: 27
Harshabad Singh, Rachel B. Keller, Kevin S. Kapner, et al.
Clinical Cancer Research (2023) Vol. 29, Iss. 22, pp. 4627-4643
Open Access | Times Cited: 27
Showing 1-25 of 27 citing articles:
Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group
M.F. Mosele, C. Benedikt Westphalen, A Stenzinger, et al.
Annals of Oncology (2024) Vol. 35, Iss. 7, pp. 588-606
Open Access | Times Cited: 80
M.F. Mosele, C. Benedikt Westphalen, A Stenzinger, et al.
Annals of Oncology (2024) Vol. 35, Iss. 7, pp. 588-606
Open Access | Times Cited: 80
Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival
Anna M. Varghese, Maria Perry, Joanne F. Chou, et al.
Nature Medicine (2025)
Open Access | Times Cited: 3
Anna M. Varghese, Maria Perry, Joanne F. Chou, et al.
Nature Medicine (2025)
Open Access | Times Cited: 3
Precision medicine for KRAS wild-type pancreatic adenocarcinomas
Imen Ben-Ammar, Adrien Rousseau, Rémy Nicolle, et al.
European Journal of Cancer (2023) Vol. 197, pp. 113497-113497
Closed Access | Times Cited: 19
Imen Ben-Ammar, Adrien Rousseau, Rémy Nicolle, et al.
European Journal of Cancer (2023) Vol. 197, pp. 113497-113497
Closed Access | Times Cited: 19
Pancreatic cancer biomarkers: A pathway to advance in personalized treatment selection
Elena Brozos-Vázquez, Marta Toledano‐Fonseca, Nicolás Costa‐Fraga, et al.
Cancer Treatment Reviews (2024) Vol. 125, pp. 102719-102719
Open Access | Times Cited: 7
Elena Brozos-Vázquez, Marta Toledano‐Fonseca, Nicolás Costa‐Fraga, et al.
Cancer Treatment Reviews (2024) Vol. 125, pp. 102719-102719
Open Access | Times Cited: 7
Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic adenocarcinoma
Matthew H. G. Katz, Gina R. Petroni, Todd W. Bauer, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 12, pp. e007586-e007586
Open Access | Times Cited: 14
Matthew H. G. Katz, Gina R. Petroni, Todd W. Bauer, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 12, pp. e007586-e007586
Open Access | Times Cited: 14
Evaluation of KRAS inhibitor-directed therapies for pancreatic cancer treatment
Szu-Aun Long, Amber M. Amparo, Grace Goodhart, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 5
Szu-Aun Long, Amber M. Amparo, Grace Goodhart, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 5
The trend toward more target therapy in pancreatic ductal adenocarcinoma
Chiara Deiana, Margherita Agostini, Giovanni Brandi, et al.
Expert Review of Anticancer Therapy (2024) Vol. 24, Iss. 7, pp. 525-565
Open Access | Times Cited: 5
Chiara Deiana, Margherita Agostini, Giovanni Brandi, et al.
Expert Review of Anticancer Therapy (2024) Vol. 24, Iss. 7, pp. 525-565
Open Access | Times Cited: 5
Molecular Subtyping and Genomic Profiling Expand Precision Medicine in KRAS Wild‐Type Pancreatic Cancer
Dan Su, Yuli Ruan, Yingfei Shi, et al.
Cancer Science (2025)
Open Access
Dan Su, Yuli Ruan, Yingfei Shi, et al.
Cancer Science (2025)
Open Access
RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms
Xiaojuan Yang, Hong Wu
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 4
Xiaojuan Yang, Hong Wu
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 4
Advances in Novel Targeted Therapies for Pancreatic Adenocarcinoma
Tuan Hoang, Erica S. Tsang
Journal of Gastrointestinal Cancer (2025) Vol. 56, Iss. 1
Closed Access
Tuan Hoang, Erica S. Tsang
Journal of Gastrointestinal Cancer (2025) Vol. 56, Iss. 1
Closed Access
Identification of Candidate Alterations Mediating KRASG12C Inhibitor Resistance in Advanced Colorectal and Pancreatic Cancers
Khalid Jazieh, Jill Tsai, Sheila Solomon, et al.
Clinical Cancer Research (2025) Vol. 31, Iss. 5, pp. 899-906
Closed Access
Khalid Jazieh, Jill Tsai, Sheila Solomon, et al.
Clinical Cancer Research (2025) Vol. 31, Iss. 5, pp. 899-906
Closed Access
Chemotherapy-free treatment targeting fusions and driver mutations in KRAS wild-type pancreatic ductal adenocarcinoma, a case series
Maahum Mehdi, Aniko Szabo, Aditya Shreenivas, et al.
Therapeutic Advances in Medical Oncology (2024) Vol. 16
Open Access | Times Cited: 2
Maahum Mehdi, Aniko Szabo, Aditya Shreenivas, et al.
Therapeutic Advances in Medical Oncology (2024) Vol. 16
Open Access | Times Cited: 2
Identifying Actionable Alterations in KRAS Wild-Type Pancreatic Cancer
Ahmed Elhariri, Jaydeepbhai Patel, Himil Mahadevia, et al.
Targeted Oncology (2024) Vol. 19, Iss. 5, pp. 679-689
Closed Access | Times Cited: 1
Ahmed Elhariri, Jaydeepbhai Patel, Himil Mahadevia, et al.
Targeted Oncology (2024) Vol. 19, Iss. 5, pp. 679-689
Closed Access | Times Cited: 1
Machine Learning Developed a MYC Expression Feature-Based Signature for Predicting Prognosis and Chemoresistance in Pancreatic Adenocarcinoma
Biao Dong, Yueshan Zhang, Han Gao, et al.
Biochemical Genetics (2024)
Closed Access | Times Cited: 1
Biao Dong, Yueshan Zhang, Han Gao, et al.
Biochemical Genetics (2024)
Closed Access | Times Cited: 1
Combination of mutations in genes controlling DNA repair and high mutational load plays a prognostic role in pancreatic ductal adenocarcinoma (PDAC): a retrospective real-life study in Sardinian population
Maria Cristina Sini, Maria Grazia Doro, Laura Frogheri, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 1
Maria Cristina Sini, Maria Grazia Doro, Laura Frogheri, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 1
Molecular and Clinical Features of Pancreatic Acinar Cell Carcinoma: A Single Institution Case Series
Ashwathy Balachandran Pillai, Mahmoud Yousef, Abdelrahman Yousef, et al.
(2024)
Open Access | Times Cited: 1
Ashwathy Balachandran Pillai, Mahmoud Yousef, Abdelrahman Yousef, et al.
(2024)
Open Access | Times Cited: 1
Loss of p53 and SMAD4 induces adenosquamous subtype pancreatic cancer in the absence of an oncogenic KRAS mutation
Daowei Yang, Xinlei Sun, Rohan Moniruzzaman, et al.
Cell Reports Medicine (2024) Vol. 5, Iss. 9, pp. 101711-101711
Open Access | Times Cited: 1
Daowei Yang, Xinlei Sun, Rohan Moniruzzaman, et al.
Cell Reports Medicine (2024) Vol. 5, Iss. 9, pp. 101711-101711
Open Access | Times Cited: 1
Real‐world genome profiling in Japanese patients with pancreatic ductal adenocarcinoma focusing on HRD implications
Toshifumi Doi, Takeshi Ishikawa, Tomoki Sakakida, et al.
Cancer Science (2024)
Open Access | Times Cited: 1
Toshifumi Doi, Takeshi Ishikawa, Tomoki Sakakida, et al.
Cancer Science (2024)
Open Access | Times Cited: 1
Combination of mutations in genes controlling DNA repair and high mutational load plays a prognostic role in pancreatic ductal adenocarcinoma (PDAC): a retrospective real-life study in Sardinian population
Maria Cristina Sini, MariaGrazia Doro, Laura Frogheri, et al.
Research Square (Research Square) (2024)
Open Access
Maria Cristina Sini, MariaGrazia Doro, Laura Frogheri, et al.
Research Square (Research Square) (2024)
Open Access
Highlights of Translational and Molecular Research Presented at the European Society for Medical Oncology Annual Meeting 2023
Maria Pouyiourou, Lea Reitnauer, Alexej Ballhausen, et al.
Oncology Research and Treatment (2024) Vol. 47, Iss. 4, pp. 149-153
Closed Access
Maria Pouyiourou, Lea Reitnauer, Alexej Ballhausen, et al.
Oncology Research and Treatment (2024) Vol. 47, Iss. 4, pp. 149-153
Closed Access
Multidisciplinary Standards and Evolving Therapies for Patients With Pancreatic Cancer
Rachael A. Safyan, Eejung Kim, Emmelie Dekker, et al.
American Society of Clinical Oncology Educational Book (2024) Vol. 44, Iss. 3
Closed Access
Rachael A. Safyan, Eejung Kim, Emmelie Dekker, et al.
American Society of Clinical Oncology Educational Book (2024) Vol. 44, Iss. 3
Closed Access
How to find a needle in a haystack: a systematic review on targeting KRAS wild-type pancreatic cancer
Antoine Mouawad, Sofia Habib, Marc Boutros, et al.
Future Oncology (2024) Vol. 20, Iss. 40, pp. 3539-3547
Closed Access
Antoine Mouawad, Sofia Habib, Marc Boutros, et al.
Future Oncology (2024) Vol. 20, Iss. 40, pp. 3539-3547
Closed Access
Role of molecular biology in the management of pancreatic cancer
Alice Boilève, Cristina Smolenschi, Aurélien Lambert, et al.
World Journal of Gastrointestinal Oncology (2024) Vol. 16, Iss. 7, pp. 2902-2914
Open Access
Alice Boilève, Cristina Smolenschi, Aurélien Lambert, et al.
World Journal of Gastrointestinal Oncology (2024) Vol. 16, Iss. 7, pp. 2902-2914
Open Access
Molecular and Clinical Features of Pancreatic Acinar Cell Carcinoma: A Single-Institution Case Series
Ashwathy Balachandran Pillai, Mahmoud Yousef, Abdelrahman Yousef, et al.
Cancers (2024) Vol. 16, Iss. 19, pp. 3421-3421
Open Access
Ashwathy Balachandran Pillai, Mahmoud Yousef, Abdelrahman Yousef, et al.
Cancers (2024) Vol. 16, Iss. 19, pp. 3421-3421
Open Access
New Therapeutic Targets in RAS Wild-type Pancreatic Cancer
Maria Diab
Current Treatment Options in Oncology (2024)
Closed Access
Maria Diab
Current Treatment Options in Oncology (2024)
Closed Access
